Company profile
Vir Biotechnology, Inc.
NASDAQ:VIRBiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (4)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| SOTROVIMAB | phase2_3 | — | 2 | no active trials |
| Elebsiran | phase2 | — | 8 | active |
| Sonavibart | phase2 | — | 2 | completed, terminated |
| Tobevibart | phase2 | — | 5 | active |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (21)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05567783 | phase2 | terminated | 2022-10-30 | 2023-05-05 | Vir Biotechnology, Inc. | A Phase 2 Study to Evaluate the Efficacy and Safety of VIR-2482 for the Prevention of Illness Due to Influenza A |
| NCT05612581 | phase1_2 | completed | 2023-05-10 | 2024-10-15 | Vir Biotechnology, Inc. | A Platform Study to Evaluate Investigational Therapies in Chronic Hepatitis B Infection |
| NCT06903338 | phase3 | active_not_recruiting | 2025-03-12 | 2026-12-31 | Vir Biotechnology, Inc. | A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV Infection |
| NCT07142811 | phase2 | active_not_recruiting | 2025-08-05 | 2026-11-01 | Vir Biotechnology, Inc. | A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV Infection |
| NCT07128550 | phase3 | active_not_recruiting | 2025-07-30 | 2026-12-01 | Vir Biotechnology, Inc. | A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide |
FDA applications (0)
No records yet.